6Avsar E, Tiftikci A, Poturoqlu S, et al. A muhicenter, random- ized, prospective study of M-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients[ J]. Turk J Gastroenteml, 2013,24 (4) :316-321.
7Ding Y. The effect of lansoprazole, an OCT inhibitor, on metform- in pharmacokinetics in healthy subjects[J]. EurJ Clin Pharmacol, 2014,70(2) :141-146.
8Rajah A. Slow spontaneous degradation of lansoprazole, omeprazole and pantoprazole tablets:isolation and structural characterization of the toxic antioxidants 3 H-benzimidazole-2-thiones [ J ]. Pharmazie, 2013,68(9) :749-754.
9Sahara S. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metaholisers compared with twice- daily omeprazole, rabeprazole or lansoprazole [ J ]. Aliment Phar- macol Ther, 2013,38 (9) : 1129-1137.
10Novotna A, Smvnalova A, Svecarova M, et al. Differential effects of omeprazole and lansoprazole enantiomers on aryl hydrocarbon re- ceptor in human hepatoeytes and cell lines[ J]. PLoS One, 2014, 9(6) :711-714.
